Key facts
- AbbVie Inc. is reportedly close to acquiring Apogee Therapeutics Inc.
- The acquisition is valued at nearly $11 billion.
- The deal is expected to be an all-cash transaction.
- The acquisition aims to bolster AbbVie's anti-inflammatory drug portfolio.
- Apogee Therapeutics develops novel therapies for inflammatory diseases.
AbbVie Inc. is reportedly in advanced negotiations to acquire Apogee Therapeutics Inc. in a deal valued at approximately $11 billion. The proposed acquisition is structured as an all-cash transaction. This strategic move is designed to enhance AbbVie's existing portfolio of anti-inflammatory drugs. The acquisition would provide AbbVie with access to Apogee's pipeline of novel therapies targeting inflammatory diseases. This potential deal underscores AbbVie's ongoing strategy of pursuing significant acquisitions to expand its therapeutic offerings and market presence. Apogee Therapeutics is known for its work in developing innovative treatments for conditions characterized by inflammation. The financial terms suggest a substantial investment by AbbVie, reflecting the perceived value of Apogee's research and development assets in the competitive biopharmaceutical landscape. The acquisition, if completed, would represent a major development for both companies, potentially reshaping aspects of the anti-inflammatory drug market.